







## RECOMBINANT INFLUENZA VACCINE (RIVs)

TRADE NAME [MANUFACTURER]	PRESENTATION	AGE INDICATION	MERCURY, $\mu\text{G}/0.5\text{ML}$	LATEX	ROUTE
Flublok Quadrivalent (RIV4) [Protein Sciences]	0.5 mL prefilled syringe	$\geq 18$ yrs	NR	No	IM
Flublok (RIV3) [Protein Sciences]	0.5 mL single-dose vial	$\geq 18$ yrs	NR	No	IM

Abbreviations: IM = intramuscular; NR = not relevant (does not contain thimerosal); yrs = years.

### RIV Hemagglutinin Content

- RIVs contain 45 $\mu\text{g}$  of HA derived from each vaccine virus per 0.5mL dose (135 $\mu\text{g}$  total for RIV3 and 180  $\mu\text{g}$  total for RIV4).

### RIV Administration

- RIV is administered intramuscularly.
  - Adults: deltoid is the preferred site.
- Detailed guidance for administration sites and needle length is available in *Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP)* at <https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html>

### RIV Contraindications and Precautions

#### Contraindications:

- History of severe allergic reaction to any component of the vaccine.
  - Information about vaccine components is located in package inserts from the manufacturer.

#### Precautions:

- Moderate to severe acute illness with or without fever.
- Guillain-Barré syndrome within 6 weeks following a previous dose of influenza vaccine.

## LIVE ATTENUATED INFLUENZA VACCINE (LAIV4)

**NOTE: LAIV4 is not recommended for use in any population for 2017-18. Content provided for information only.**

TRADE NAME [MANUFACTURER]	PRESENTATION	AGE INDICATION	MERCURY, $\mu\text{G}/0.5\text{ML}$	LATEX	ROUTE
FluMist Quadrivalent (LAIV4) [MedImmune]	0.2 mL single-dose prefilled intranasal sprayer	2 through 49 yrs	NR	No	NAS

Abbreviations: NAS = intranasal; NR = not relevant (does not contain thimerosal); yrs = years.

### LAIV Administration

**LAIV is not recommended for use in any population for 2017-18.** Providers who use it should note the following:

- LAIV is administered intranasally using the supplied prefilled, single-use sprayer containing 0.2 mL of vaccine.
  - Half of the total sprayer contents is sprayed into the first nostril while the recipient is in the upright position.
  - The attached divider clip is removed and the second half of the dose administered into the other nostril.
- If the vaccine recipient sneezes immediately after administration, the dose should not be repeated.
- If nasal congestion impedes delivery of the vaccine to the nasopharyngeal mucosa, deferral should be considered, or another age-appropriate vaccine should be administered.

### LAIV Contraindications and Precautions

#### Contraindications:

- History of severe allergic reaction to any vaccine component or after previous dose of any influenza vaccine;
  - Information about vaccine components is located in package inserts from the manufacturer.
- Concomitant aspirin or salicylate-containing therapy in children and adolescents;
- Children aged 2 through 4 years who have received a diagnosis of asthma or whose parents or caregivers report that a health care provider has told them during the preceding 12 months that their child had wheezing or asthma or whose medical record indicates a wheezing episode has occurred during the preceding 12 months;
- Children and adults who are immunocompromised due to any cause (including immunosuppression caused by medications or by HIV infection);
- Close contacts and caregivers of severely immunosuppressed persons who require a protected environment;
- Pregnancy;
- Receipt of influenza antiviral medication within previous 48 hours.

#### Precautions:

- Moderate to severe acute illness with or without fever;
- History of Guillain-Barré syndrome within 6 weeks of receipt of influenza vaccine;
- Asthma in persons aged  $\geq 5$  years;
- Other underlying medical conditions that might predispose to complications attributable to severe influenza (e.g., chronic pulmonary, cardiovascular [except isolated hypertension], renal, hepatic, neurologic, hematologic, or metabolic disorders (including diabetes mellitus).

#### VACCINE ABBREVIATIONS

- IIV** = Inactivated Influenza Vaccine.
  - IIV3** = Trivalent Inactivated Influenza Vaccine;
  - IIV4** = Quadrivalent Inactivated Influenza Vaccine.
- RIV** = Recombinant Influenza Vaccine.
  - RIV3** = Trivalent Recombinant Influenza Vaccine;
  - RIV4** = Quadrivalent Recombinant Influenza Vaccine.
- LAIV4** = Quadrivalent Live Attenuated Influenza Vaccine
- IIV, RIV, and LAIV denote vaccine categories; numeric suffix denotes number of antigens in the vaccine,
- When referring specifically to adjuvanted vaccine, the prefix "a" is used (e.g., **aIIV3**).
- When referring specifically to cell culture-based vaccine, the prefix "cc" is used (e.g., **ccIIV4**).
- When referring specifically to High-dose vs. Standard-dose vaccines, the prefixes "HD-" and "SD-" are used (e.g., **HD-IIV3** vs. **SD-IIV3** and **SD-IIV4**).